Diabetic Nephropathy News | Diabetes & Renal Research Studies

Diabetic Nephropathy

DIABETIC NEPHROPATHY

Canagliflozin Protects Against Renal Function Decline in Advanced Diabetic CKD

WASHINGTON—Canagliflozin showed a protective effect against kidney function decline in patients with type 2 diabetes and a baseline estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2, new study findings presented at the American Society of Nephrology’s Kidney Week 2019 meeting suggest. The findings are from a post-hoc subgroup analysis of the phase 3 CREDENCE…
kidney cross section

FDA Approves Canagliflozin for Diabetic Kidney Disease

FDA’s approval of canagliflozin for slowing progression of diabetic nephropathy in patients with type 2 diabetes makes the drug the first new treatment option in nearly 20 years indicated for slowing diabetic kidney disease in these patients.

Diabetes Tx Gains Fast Track Designation for Kidney Disease

The FDA has granted Fast Track designation to dapagliflozin (Farxiga; AstraZeneca) as a possible treatment to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease.